Table 2.
Patient characteristics and treatment history
| N | Dutch PWH | Swedish PWH |
|---|---|---|
| 43 | 28 | |
| Median (IQR) or number (%) | ||
| Age (y) | 27 (22‐30) | 25 (22‐31) |
| Haem type A (%) | 37 (86%) | 25 (89%) |
| HIV positive (%) | 4 (9.3%) | 1 (3.6%) |
| HCV positive (%) | 23 (53.5%) | 7 (25.0%) |
| Age start prophylaxis (y) | 5.0* (3.3‐5.6) | 1.7 (1.3‐3.0) |
| Weekly dose (IU/kg) | 41* (31‐51) | 82 (59‐96) |
| Joint health (HJHS, 0‐144) | 9* (2‐18) | 4.5 (2.3‐7) |
| Limitations (HAL, 100‐0) | 94* (82‐98) | 99 (94‐100) |
| Physical functioning (SF‐36PF, 100‐0) | 95‡ (75‐100) | 100 (95‐100) |
Dutch PWH score significantly higher than Swedish PWH with regard to treatment history (* P < 0.01), joint health (* P < 0.01), self‐reported limitations (* P < 0.01) and physical functioning (‡ P < 0.05), but have lower weekly treatment dose (* P < 0.01).